Review Article| Volume 34, ISSUE 1, P45-69, February 2020

Radiation Therapy for Prostate Cancer

Published:October 28, 2019DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2019.
        CA Cancer J Clin. 2019; 69: 7-34
        • Network, N.C.C
        Prostate cancer (version 1.2019).
        (Available at:) (Accessed January 15, 2019)
        • Sanda M.G.
        • Cadeddu J.A.
        • Kirby E.
        • et al.
        Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options.
        J Urol. 2018; 199: 683-690
        • Bekelman J.E.
        • Rumble R.B.
        • Chen R.C.
        • et al.
        Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.
        J Clin Oncol. 2018; (JCO1800606. [Epub ahead of print])
        • Sanda M.G.
        • Cadeddu J.A.
        • Kirby E.
        • et al.
        Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options.
        J Urol. 2018; 199: 990-997
        • Dall'Era M.A.
        • Albertsen P.C.
        • Bangma C.
        • et al.
        Active surveillance for prostate cancer: a systematic review of the literature.
        Eur Urol. 2012; 62: 976-983
        • Delongchamps N.B.
        • Singh A.
        • Haas G.P.
        The role of prevalence in the diagnosis of prostate cancer.
        Cancer Control. 2006; 13: 158-168
        • Sathianathen N.J.
        • Konety B.R.
        • Crook J.
        • et al.
        Landmarks in prostate cancer.
        Nat Rev Urol. 2018; 15: 627-642
        • Litwin M.S.
        • Tan H.J.
        The diagnosis and treatment of prostate cancer: a review.
        JAMA. 2017; 317: 2532-2542
        • Hu J.C.
        • Gu X.
        • Litsitz S.R.
        • et al.
        Comparative effectiveness of minimally invasive vs open radical prostatectomy.
        JAMA. 2009; 302: 1557-1564
        • Trinh Q.D.
        • Bjartell A.
        • Freedland S.J.
        • et al.
        A systematic review of the volume-outcome relationship for radical prostatectomy.
        Eur Urol. 2013; 64: 786-798
        • Michalski J.M.
        • Moughan J.
        • Purdy J.
        • et al.
        Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial.
        JAMA Oncol. 2018; 4: e180039
        • Zumsteg Z.S.
        • Spratt D.E.
        • Pei I.
        • et al.
        A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
        Eur Urol. 2013; 64: 895-902
        • Keane F.K.
        • Chen M.H.
        • Zhang D.
        • et al.
        Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
        Cancer. 2015; 121: 2713-2719
        • Royce T.J.
        • Lee D.H.
        • Keum N.
        • et al.
        Conventional versus hypofractionated radiation therapy for localized prostate cancer: a meta-analysis of randomized noninferiority trials.
        Eur Urol Focus. 2019; 5: 577-584
        • Hoffman K.E.
        • Voong K.R.
        • Levy L.B.
        • et al.
        Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer.
        J Clin Oncol. 2018; 36: 2943-2949
        • Dubray B.M.
        • Salleron J.
        • Guerif S.G.
        • et al.
        Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial.
        J Clin Oncol. 2016; 34(Suppl 15)
        • Nabid A.
        • Carrier N.
        • Martin A.G.
        • et al.
        Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial.
        Eur Urol. 2018; 74: 432-441
        • Albertsen P.
        Androgen deprivation in prostate cancer--step by step.
        N Engl J Med. 2009; 360: 2572-2574
        • Fang L.C.
        • Merrick G.S.
        • Wallner K.E.
        Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?.
        Oncology (Williston Park). 2010; 24 (798): 790-796
        • Morris W.J.
        • Tyldesley S.
        • Rodda S.
        • et al.
        Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
        • Rodda S.
        • Tyldesley S.
        • Morris W.J.
        • et al.
        ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2017; 98: 286-295
        • Kishan A.U.
        • Cook R.R.
        • Ciezki J.P.
        • et al.
        Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer.
        JAMA. 2018; 319: 896-905
        • Rosenthan S.A.
        • Hu C.
        • Sartor O.
        • et al.
        Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial.
        J Clin Oncol. 2019; 37: 1159-1168
        • Kellokumpu-Lehtinen P.-L.I.
        • Hjalm-Eriksson M.
        • Astrom L.
        • et al.
        A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: results of SPCG-13 trial.
        J Clin Oncol. 2018; 36: 5000
        • Lawton C.A.
        • DeSilvio M.
        • Roach M.
        • et al.
        An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
        Int J Radiat Oncol Biol Phys. 2007; 69: 646-655
        • Pommier P.
        • Chabaud S.
        • Lagrange J.L.
        • et al.
        Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study.
        Int J Radiat Oncol Biol Phys. 2016; 96: 759-769
        • Schuster D.M.
        • Savir-Baruch B.
        • Nieh P.T.
        • et al.
        Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
        Radiology. 2011; 259: 852-861
        • Seisen T.
        • Vetterlein M.W.
        • Karabon P.
        • et al.
        Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis.
        Eur Urol. 2017; ([pii:S0302-2838(17)30697-8])
        • Abdollah F.
        • Karnes R.J.
        • Suardi N.
        • et al.
        Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
        J Clin Oncol. 2014; 32: 3939-3947
        • Attar R.M.
        • Takimoto C.H.
        • Gottardis M.M.
        Castration-resistant prostate cancer: locking up the molecular escape routes.
        Clin Cancer Res. 2009; 15: 3251-3255
        • Damodaran S.
        • Kyriakopoulos C.E.
        • Jarrard D.F.
        Newly diagnosed metastatic prostate cancer: has the paradigm changed?.
        Urol Clin North Am. 2017; 44: 611-621
        • Slaoui A.
        • Albisinni S.
        • Aoun F.
        • et al.
        A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?.
        World J Urol. 2019; ([pii:S0302-2838(17)30697-8])
        • Palma D.A.
        • Olsen R.A.
        • Harrow S.
        • et al.
        Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial.
        Int J Radiat Oncol Biol Phys. 2018; 102: S3-S4
        • Sineshaw H.M.
        • Gray P.J.
        • Efstathiou J.A.
        • et al.
        Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base.
        Eur Urol. 2015; 68: 768-774
      1. Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer.
        N Engl J Med. 2017; 376: 417-428
        • Carrie C.
        • Hasbini A.
        • de Laroche G.
        • et al.
        Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
        Lancet Oncol. 2016; 17: 747-756
        • Pollack A.
        • Karrison T.G.
        • Balogh Jr, A.G.
        • et al.
        Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG oncology/RTOG 0534 SPPORT trial.
        Int J Radiat Oncol Biol Phys. 2018; 102: 1605
        • Fossa S.D.
        • Wiklund F.
        • Klepp O.
        • et al.
        Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7.
        Eur Urol. 2016; 70: 684-691

      Linked Article

      • Erratum
        Hematology/Oncology ClinicsVol. 34Issue 2
        • Preview
          For the article on “Radiation Therapy for Prostate Cancer” in the February 2020 issue of Hematology/Oncology Clinics of North America (Volume 34, Issue 1), a few errors occurred regarding the mentions of the Tables. On page 48, a mention of Table 1 was erroneously placed in the section, “Intermediate-Risk Disease”. On page 51, a mention of Table 1 was erroneously placed in the section, “Definition and historical perspective”. Also on page 51, at the end of the section, “Definition and historical perspective”, the mention of Table 6 was incorrectly labeled as Table 7.
        • Full-Text
        • PDF